🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 13 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
07/05/2021 30,58 31,53 30,27 30,45 +1,06% 4,10% 560.300
06/05/2021 30,28 30,79 28,88 30,13 -2,62% 6,31% 1.160.100
05/05/2021 32,57 33,39 30,85 30,94 -5,38% 7,80% 358.000
04/05/2021 33,98 35,12 32,63 32,70 -4,11% 7,33% 659.700
03/05/2021 34,50 34,97 33,93 34,10 +1,04% 3,01% 212.900
30/04/2021 32,75 33,93 32,61 33,75 +0,99% 4,03% 324.900
29/04/2021 34,79 34,79 33,22 33,42 -3,13% 4,51% 235.800
28/04/2021 34,17 34,89 33,88 34,50 -0,69% 2,96% 423.300
27/04/2021 36,38 36,44 33,68 34,74 -2,63% 7,59% 583.500
26/04/2021 35,88 36,11 35,17 35,68 -0,25% 2,62% 621.100
23/04/2021 35,00 36,20 34,63 35,77 +3,08% 4,49% 552.800
22/04/2021 33,87 34,95 32,81 34,70 +2,21% 6,32% 408.900
21/04/2021 31,82 33,99 31,44 33,95 +6,26% 8,01% 429.700
20/04/2021 31,62 32,35 31,24 31,95 -0,34% 3,51% 672.400
19/04/2021 32,68 33,35 31,84 32,06 -3,23% 4,61% 301.100
16/04/2021 34,85 35,45 32,85 33,13 -5,32% 7,45% 378.800
15/04/2021 33,59 35,50 33,33 34,99 +5,36% 6,46% 596.200
14/04/2021 32,61 33,87 32,36 33,21 +2,34% 4,63% 506.100
13/04/2021 30,23 32,63 30,23 32,45 +6,43% 7,94% 559.100
12/04/2021 31,29 31,34 29,18 30,49 -2,59% 6,90% 554.000
09/04/2021 31,18 32,04 30,68 31,30 +1,29% 4,35% 316.100
08/04/2021 31,01 31,97 30,40 30,90 +0,78% 5,06% 558.700
07/04/2021 31,51 31,58 30,53 30,66 -2,97% 3,33% 261.200
06/04/2021 32,29 33,11 31,34 31,60 -2,98% 5,48% 366.700
05/04/2021 31,58 32,58 31,00 32,57 +12,97% 5,00% 568.100
01/04/2021 28,59 29,86 28,16 28,83 +2,67% 5,95% 449.200
31/03/2021 28,10 28,59 27,04 28,08 +0,07% 5,52% 1.053.500
30/03/2021 28,27 28,38 26,69 28,06 -2,87% 5,98% 1.116.000
29/03/2021 32,39 32,43 28,82 28,89 -11,68% 11,15% 500.600
26/03/2021 33,00 33,80 30,86 32,71 -2,15% 8,91% 450.100